セッション情報

一般演題 (示説)

第53回・2015年・京都
一般演題 (示説)
示説76
Colon:Colorectal Cancer
開催回
第53回・2015年・京都

Targeted therapy for Ras in colorectal cancer with Kras mutation

演題番号 : P76-1

Kato Junko:1、Mori Ryutaro:1、Tanahashi Toshiyuki:1、Matsuhashi Mobuyuki:1、Futamura Manabu:1、Takahashi Takao:1、Yoshida Kazuhiro:1

1:Surgical oncology, Hospital, Gifu University

Targeted therapy for Ras in colorectal cancer with Kras mutation

Granular cell tumors of the colorectum: Histopathological and immunohistochemical evaluation of 30 cases

演題番号 : P76-2

Kim Dong Yi:1、Kim Ho Gun:1、Ryu Seong Yeob:1、Lee Jae Hyuk:1

1:Gastroenterologic Surgery, Department of Surgery, Chonnam National University Medical School, Korea

Granular cell tumors of the colorectum: Histopathological and immunohistochemical evaluation of 30 cases

Usefulness of screening using urinary porphyrins for colorectal cancer patients as a new tumor marker

演題番号 : P76-3

Kamada Yosuke:1、Murayama Yasutosi:1、Arita Tomohiro:1、Kosuga Toshiyuki:1、Konishi Hirotaka:1、Morimura Ryo:1、Komatsu Shuhei:1、Shiozaki Atsushi:1、Kuriu Yoshiaki:1、Ikoma Hisashi:1、Nakanishi Masayoshi:1、Ichikawa Daisuke:1、Hujiwara Hitoshi:1、Okamoto Kazuma:1、Otsuji Eigo:1

1:Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine

Usefulness of screening using urinary porphyrins for colorectal cancer patients as a new tumor marker

Prognostic impact of enhancer of zeste homologue 2 (EZH2) in patients underwent hepatectomy for colorectal liver metastases who received preoperative oxaliplatin-based chemotherapy

演題番号 : P76-4

Ohuchi Mayuko:1、Sakamoto Yasuo:1、Nakamura Kenichi:1、Kosumi Keisuke:1、Tokunaga Ryuma:1、Harada Kazuto:1、Shigaki Hironobu:1、Kurashige Junji:1、Iwatsuki Masaaki:1、Baba Yoshifumi:1、Miyamoto Yuji:1、Yoshida Naoya:1、Baba Hideo:1

1:Gastrointestinal Surgery, Faculty of Life Sciences, Kumamoto University

Prognostic impact of enhancer of zeste homologue 2 (EZH2) in patients underwent hepatectomy for colorectal liver metastases who received preoperative oxaliplatin-based chemotherapy

Long-term outcome and prognostic factors for recurrence after tegafur-uracil plus leucovorin adjuvant therapy in colorectal cancer patients

演題番号 : P76-5

Watanabe Makoto:1、Murakami Masahiko:1、Ozawa Yoshiaki:1、Goto Satoru:1、Fujimori Akira:1、Otsuka Koji:1、Aoki Takeshi:1

1:Department of Gastroenterological & General Surgery, School of Medicine, Showa University

Long-term outcome and prognostic factors for recurrence after tegafur-uracil plus leucovorin adjuvant therapy in colorectal cancer patients

Impact of lymph node ratio on oncologic outcomes in ypStage III rectal cancer treated with neoadjuvant chemoradiotherapy followed by total mesorectal excision, and postoperative adjuvant chemotherapy

演題番号 : P76-6

Kim Jae-sung:1、Koo Taeryool:3、Song Changhoon:1、Kim Kyubo:3、Chie Eui Kyu:3、Kang Sung-bum:2、Lee Keun-wook:4、Kim Jee Hyun:4、Jeong Seung-yong:5、Kim Tae-you:6

1:Department of Radiation Oncology, Seoul National University Bundnag Hospital、2:Department of Surgery, Seoul National University Bundnag Hospital、3:Department of Radiation Oncology, Seoul National University Hospital、4:Department of Internal Medicine, Seoul National University Bundnag Hospital、5:Department of Surgery, Seoul National University Hospital、6:Department of Internal Medicine, Seoul National University Hospital

Impact of lymph node ratio on oncologic outcomes in ypStage III rectal cancer treated with neoadjuvant chemoradiotherapy followed by total mesorectal excision, and postoperative adjuvant chemotherapy

Extracellular signal-regulated kinase and AKT activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition

演題番号 : P76-7

Tanahashi Toshiyuki:1、Osada Shinji:1、Kato Junko:1、Mori Ryutaro:1、Matsui Satoshi:1、Imai Hisashi:1、Sasaki Yoshiyuki:1、Tanaka Yoshihiro:1、Okumura Naoki:1、Matsuhashi Nobuhisa:1、Yamaguchi Kazuya:1、Futamura Manabu:1、Yoshida Kazuhiro:1

1:Surgical Oncology, Graduate School of Medicine, Gifu University

Extracellular signal-regulated kinase and AKT activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition

Interim results of the dose-escalation of REGorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study

演題番号 : P76-8

Nishitai Ryuta:1、Manaka Dai:1、Amaike Hisashi:2、Nozaki Akira:3、Kanai Masashi:4、Yamaguchi Daisuke:4、Yazawa Takeshi:5、Kawashima Kazuhiko:6、Ikeda Fusao:7、Konishi Sayuri:1、Hamasu Shinya:1、Kanto Satoshi:1、Kanai Shunpei:1、Mitsuoka Eisei:1、Kudo Ryo:1

1:Department of Surgery, Kyoto-Katsura Hospital、2:kameoka Municipal Hospital、3:Kyoto Miniren Chuo Hospital、4:Department of Clinical Oncology, Hospital, Kyoto University、5:Shiga Medical Center for Adults、6:Japanese Red Cross Otsu Hospital、7:Kohka Public Hospital

Interim results of the dose-escalation of REGorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study